Targeted synthetic drugs

POS0482 EFFICACY AND SAFETY OF BARICITINIB IN DIFFERENT DOSES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
S. I. Sadik, M. R. Choudhury

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 751-752; DOI: 10.1136/annrheumdis-2024-eular.166
POS0489 COMPARISON OF THE EFFECTS OF BARICITINIB AND ABATACEPT ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROPENSITY SCORE MATCHING ANALYSIS
S. Asai, N. Takahashi, K. Terabe, Y. Yoshioka, T. Kojima, T. Kobayakawa, Y. Sobue, T. Watanabe, Y. Hirano, Y. Kanayama, T. Kato, M. Hanabayashi, M. Suzuki, S. Imagama

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 763-764; DOI: 10.1136/annrheumdis-2024-eular.933
POS0635 PREDICTORS OF CLINICAL REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAK INHIBITORS: THE TBCR STUDY
S. Asai, K. Terabe, N. Takahashi, Y. Yoshioka, T. Watanabe, T. Kojima, T. Kobayakawa, Y. Sobue, Y. Kanayama, T. Matsumoto, Y. Hirano, T. Kato, T. Fujibayashi, M. Hanabayashi, T. Nishiume, M. Suzuki, S. Imagama, On Behalf of TBCR Group

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 767-768; DOI: 10.1136/annrheumdis-2024-eular.1109
POS0637 COST-EFFECTIVENESS ANALYSIS OF UPADACITINIB VERSUS ALTERNATIVE TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO TNFi IN THE UNITED KINGDOM
P. C. Taylor, A. Kadakia, Y. Song, S. Strengholt, M. Fillbrunn, A. Jiang, M. Buch

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 769; DOI: 10.1136/annrheumdis-2024-eular.1347
POS0639 BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASE
G. R. Burmester, E. Mysler, P. C. Taylor, L. E. Kristensen, S. Hall, B. Wick-Urban, A. Garrison, T. Gao, N. Khan, S. Strengholt, R. Fleischmann

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 770-771; DOI: 10.1136/annrheumdis-2024-eular.1416
POS0641 RESEARCH ON ANEMIA IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING JAK INHIBITORS
Y. Takeuchi, M. Konishi, H. Hirabayashi, M. Tokuda

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 773-774; DOI: 10.1136/annrheumdis-2024-eular.1450
POS0624 REAL-WORLD EFFECTIVENESS OF TOFACITINIB IN MONOTHERAPY OR IN COMBINATION WITH csDMARDs IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS: A COLLABORATION BETWEEN DUTCH REGISTRIES (TOFADUDAP STUDY)
I. Nevins, A. A. Den Broeder, P. S. M. Groenen, P. D. M. De Buck, F. Reimann, R. Bos, W. Drossaers-Bakker, M. Hegeman, H. Van Groenendael, H. K. Glas, T. Huizinga, C. F. Allaart, S. A. Bergstra

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 775-776; DOI: 10.1136/annrheumdis-2024-eular.1463
POS0625 EXPLORING THE DETERMINANTS OF THE JAKi BONUS IN REAL-WORLD OBSERVATIONAL DATA
D. C. Diederik, P. Durez, J. Lenaerts, R. Westhovens, P. Verschueren

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 777-778; DOI: 10.1136/annrheumdis-2024-eular.1470
POS0650 EVALUATION OF THE SURVIVAL AND SAFETY OF BIOLOGIC AND TARGETED SYNTHETIC DMARD IN PATIENTS WITH DIFFICULT-TO-TREAT RA USING DATA FROM THE BIOBADASER 3.0 REGISTRY
A. Quevedo-Rodríguez, L. Otero-Varela, F. Sánchez-Alonso, Y. Perez-Vera, F. J. Manero Ruiz, C. Campos Fernández, S. Manrique-Arija, P. Vela Casasempere, A. J. Mera-Varela, C. Diaz-Torne, A. Movasat, B. Garcia-Magallon, I. Ros, C. Perez-Garcia, I. Castrejon, On Behalf of BIOBADASER Working Group

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 785; DOI: 10.1136/annrheumdis-2024-eular.1760
POS1034 EFFICACY AND SAFETY OF ADD-ON GENERIC TOFACITINIB EXTENDED RELEASE IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS PATIENTS HAVING INADEQUATE RESPONSE TO DISEASE-MODIFYING ANTIRHEUMATOID DRUGS: REAL-WORLD STUDY FROM EASTERN PART OF INDIA
B. Choudhuri

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 791; DOI: 10.1136/annrheumdis-2024-eular.2152

Main menu

Targeted synthetic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Targeted synthetic drugs

Pages